Imugene Limited (ASX:IMU) has received a Notice of Grant from the US Patent and Trademark Office for its patent application for the HER-Vaxx cancer immunotherapy, currently in Phase II development for HER-2+ gastric cancer.
The patent titled ‘A vaccine composition and uses thereof’ protects the method of composition and method of use of Imugene’s HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu.
HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US7 billion per annum drug Herceptin.
ASX News:— Imugene | Cancer Immunotherapies (@TeamImugene) January 13, 2020
Imugene HER-Vaxx Immunotherapy Patent Granted in United States.
> Core US patent granted in world’s largest pharmaceutical market;
> Patent provides method of composition and method of use protection to 2036.
https://t.co/cUry3A5Xvo#Immunotherapy #biotech $IMU pic.twitter.com/eIYwLJSqLZ
HER-Vaxx has successfully completed a Phase Ib study in gastric cancer and the current stage of development is a Phase II study in gastric cancer.
Imugene managing director and CEO Leslie Chong said: “Attaining the key US patent is an important milestone.
“This adds extra value to HER-Vaxx as this will protect it in the world’s largest pharmaceutical market until 2036.”